Orpyx Technology Helps Patient with Prevention and Early Detection of Ulceration

Case Study Shows Effective Offloading
for SurroSense Rx®

Calgary, AB, Canada, December 7, 2017  – Orpyx Medical Technologies Inc. announced today the American Society of Plastic Surgeons published “Novel Pressure-Sensing Smart Insole System Used for the Prevention of Pressure Ulceration in the Insensate Foot Case Report”. This case study explores the use of Orpyx’s SurroSense Rx® system for a patient with spina bifida, history of clubfoot, 20 operations to their right leg, and 3 years of unsuccessful wound management.

The patient was fitted with the SurroSense Rx system to enable ongoing plantar pressure feedback and monitored for 89 days. The device provided the patient and practitioner access to the data collected by the device which included average daily use, alert offloading, effectiveness and percentage of alerts by foot region.

At the end of the monitoring period, no recurrent ulcerative events occurred. The results of the study showed daily use of the device was an average of 8.52 hours/day and the patient received more alerts on the non-injured foot than the surgical right midfoot. According to the study, the device provided unique feedback and was able to effectively monitor patient compliance.

“Patients respond to easy-to-use wearable real-time monitoring and feedback.” said Dr. Breanne Everett, CEO & co-founder of Orpyx Medical Technologies Inc. “This case demonstrates how the SurroSense Rx helps solve the challenge of patient adherence and with earlier detection of ulceration. The absence of ulcerative events over the monitoring period is extremely encouraging.”

About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
+1 403 460 0216 ext. 501

Chan Mean
Chan Mean